Update on vaccine myocarditis

Yellow card schemeShow more

https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting

As of 23 November 2022, (UK)

Pfizer/BioNTech, monovalent and bivalent

177,925 Yellow Cards have been reported

AstraZeneca

246,866 have been reported

Moderna, monovalent and bivalent

47,045 have been reported

Novavax

52 reports

Brand of vaccine was not specified

2,130 reports

Total reports

474,018

Overall reporting rate

Around 2 to 5 Yellow Cards per 1,000 doses administered

In the 28 days

Pfizer/BioNTech, + 2,499 reports

AstraZeneca, + 228

Moderna, + 1,099

Novavax, + 15

Brand not specified, + 154

For all COVID-19 vaccines

injection-site reactions (sore arm for example)

generalised symptoms such as ‘flu-like’ illness

headache, chills, fatigue (tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, rapid heartbeat

they may be reported more frequently in younger adults

Overall, our advice remains that the benefits of the vaccines outweigh the risks in the majority of people.

The benefits of the vaccines in preventing COVID-19 and serious complications associated with COVID-19 far outweigh any currently known side effects in the majority of patients.

Don’t wait for someone else to report it
https://www.gov.uk/drug-safety-update/yellow-card-please-help-to-reverse-the-decline-in-reporting-of-suspected-adverse-drug-reactions

It is estimated that only 10% of serious reactions and between 2 and 4% of non-serious reactions are reported.

Google YT guidelines
https://support.google.com/youtube/answer/9891785

Claims that an approved COVID-19 vaccine will cause death, infertility, miscarriage, autism, or contraction of other infectious diseases

https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna

4.4 Special warnings and precautions for use

Hypersensitivity and anaphylaxis
Anaphylaxis has been reported in individuals who have received Spikevax.

Close observation for at least 15 minutes is recommended following vaccination.

Myocarditis and pericarditis

There is an increased risk for myocarditis and pericarditis following vaccination with Spikevax.

Few days, primarily occurred within 14 days,

more often after the second dose,

more often in younger males

risk profile appears to be similar for the second and the third dose

Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general.

Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis.

Vaccinated individuals should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis,

such as (acute or persisting) chest pain, shortness of breath or palpitations following vaccination.

Healthcare professionals should consult guidance and/or specialists to diagnose and treat this condition.

Who can get a COVID-19 vaccine
https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/

Everyone aged 5 (on or before 31 August 2022) and over can get a 1st and 2nd dose of the COVID-19 vaccine.

People aged 16 and over, and some children aged 12 to 15, can also get a booster dose.

Hypertension after COVID-19 vaccination
https://pubmed.ncbi.nlm.nih.gov/34985455/
Italian research